Literature DB >> 21633603

Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma.

Qing He1, Yang Liu, Qing Zou, Yong-Song Guan.   

Abstract

Transcatheter arterial chemoembolization (TACE) has become the standard treatment modality for unresectable hepatocellular carcinoma (HCC). Nonetheless, the clinical outcomes in patients with unresectable HCC are often unsatisfactory, especially in those with recurrent HCC. H101, an E1B gene deleted adenovirus, is known to have a significant antitumor activity. In addition, local injection of H101 can enhance the effect of antitumor therapies (chemotherapy and radiotherapy). Transarterial H101 gene injection in combination with TACE may help to control refractory and recurrent HCC. In this study, we report a 55-year-old patient with recurrent HCC which was treated with transarterial injection of H101 in combination with TACE, leading to a good clinical prognosis of the patient.

Entities:  

Keywords:  H101; Hepatocellular carcinoma; Therapy; Transcatheter arterial chemoembolization

Mesh：

Substances：

Year:  2011        PMID： 21633603      PMCID： PMC3098405          DOI： 10.3748/wjg.v17.i18.2353

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  11 in total

Review 1.  Viral oncolysis.

Authors:  John T Mullen; Kenneth K Tanabe
Journal:  Oncologist       Date:  2002

2.  a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Authors:  F R Khuri; J Nemunaitis; I Ganly; J Arseneau; I F Tannock; L Romel; M Gore; J Ironside; R H MacDougall; C Heise; B Randlev; A M Gillenwater; P Bruso; S B Kaye; W K Hong; D H Kirn
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

3.  Multigene expression from a replicating adenovirus using native viral promoters.

Authors:  Maxine Bauzon; Daniel Castro; Michael Karr; Lynda K Hawkins; Terry W Hermiston
Journal:  Mol Ther       Date:  2003-04       Impact factor: 11.454

4.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

Authors:  J Nemunaitis; F Khuri; I Ganly; J Arseneau; M Posner; E Vokes; J Kuhn; T McCarty; S Landers; A Blackburn; L Romel; B Randlev; S Kaye; D Kirn
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

Review 5.  Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials.

Authors:  D Kirn
Journal:  Expert Opin Biol Ther       Date:  2001-05       Impact factor: 4.388

6.  Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2.

Authors:  C A Benedict; P S Norris; T I Prigozy; J L Bodmer; J A Mahr; C T Garnett; F Martinon; J Tschopp; L R Gooding; C F Ware
Journal:  J Biol Chem       Date:  2000-10-24       Impact factor: 5.157

7.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Authors:  Josep M Llovet; Maria Isabel Real; Xavier Montaña; Ramon Planas; Susana Coll; John Aponte; Carmen Ayuso; Margarita Sala; Jordi Muchart; Ricard Solà; Joan Rodés; Jordi Bruix
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

Review 8.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

Review 9.  Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.

Authors:  Terry W Hermiston; Irene Kuhn
Journal:  Cancer Gene Ther       Date:  2002-12       Impact factor: 5.987

10.  A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.

Authors:  Hilde Stubdal; Noah Perin; Marilyn Lemmon; Patricia Holman; Maxine Bauzon; Philip M Potter; Mary K Danks; Ali Fattaey; Thomas Dubensky; Leisa Johnson
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701
View more
  5 in total

1.  Puncture injection of para-toluenesulfonamide combined with chemoembolization for advanced hepatocellular carcinoma.

Authors:  Qing He; An-Ren Kuang; Yong-Song Guan; Yue-Qing Liu
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

2.  The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma.

Authors:  Frazer Warricker; Salim I Khakoo; Matthew D Blunt
Journal:  J Transl Genet Genom       Date:  2021-08-04

Review 3.  Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment.

Authors:  Tonglei Fang; Junyuan Xiao; Yiran Zhang; Haiyan Hu; Yueqi Zhu; Yingsheng Cheng
Journal:  Quant Imaging Med Surg       Date:  2021-06

Review 4.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

Authors:  William S M Wold; Karoly Toth
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

5.  Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).

Authors:  Xiao-Jun Lin; Qi-Jiong Li; Xiang-Ming Lao; Han Yang; Sheng-Ping Li
Journal:  BMC Cancer       Date:  2015-10-15       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.